<DOC>
	<DOCNO>NCT01654120</DOCNO>
	<brief_summary>The purpose study determine effect add liraglutide high dose insulin therapy compare high dose insulin therapy alone patient insulin-treated Type 2 diabetes insulin requirement &gt; 100 unit insulin per day .</brief_summary>
	<brief_title>Study Effectiveness Liraglutide Added High Dose Insulin Type II Diabetics</brief_title>
	<detailed_description>40 subject Type 2 diabetes use &gt; 100 unit insulin per day without metformin HbA1c &gt; 6.5 % randomize 2 treatment group : treatment group liraglutide add insulin control group insulin uptitration 6 month . Primary endpoint compare group HbA1c 6 month . Secondary endpoint include weight , total daily insulin dose , percent time euglycemic , hyperglycemic , hypoglycemic range continuous glucose monitor ( CGM ) , effect GlycoMark hs-CRP . Safety endpoint include incidence hypoglycemia incidence gastrointestinal side effect .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>1 . Male female patient Type 2 diabetes HbA1c 6.5 10 % treated intensive insulin therapy ( MDI CSII , include U500 insulintreated patient ) use &gt; 100 unit insulin , without stable dose oral insulin sensitize medication , least three month . 2 . Aged 18 80 year . 3 . Females childbearing potential must use adequate form contraception . 4 . Patient willing monitor BG four time daily , use CGM , comply studyrelated protocol . 1 . Type 1 diabetes . 2 . Use GLP1 receptor agonist within previous three month . 3 . Use DPP4 inhibitor oral insulin secretagogues within previous three month . 4 . Use glucocorticoid ( except inhale ) . 5 . Use experimental drug within previous three month . 6 . Known suspected allergy liraglutide , Novolog Levemir . 7 . Personal family history medullary carcinoma thyroid MEN2 . 8 . Concomitant chronic renal disease creatinine &gt; 1.5 % . 9 . Concomitant chronic hepatic , gastrointestinal illness ( include pancreatitis active cardiovascular disease except stable exertional angina ) . 10 . Inability unwillingness monitor BG , use CGM , comply study protocol . 11 . Women childbearing potential unwilling use adequate contraception , intend become pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>insulin</keyword>
	<keyword>Type II Diabetes</keyword>
	<keyword>liraglutide</keyword>
	<keyword>Glucagon-Like Peptide 1</keyword>
</DOC>